IQVIA Holdings Inc. (NYSE:IQV) Given Average Rating of “Moderate Buy” by Brokerages

Shares of IQVIA Holdings Inc. (NYSE:IQV) have earned an average rating of “Moderate Buy” from the twenty-one analysts that are currently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a hold recommendation, thirteen have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $249.1875.

IQV has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, December 20th. Morgan Stanley boosted their price target on IQVIA from $250.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, December 1st. Barclays set a $230.00 price target on IQVIA in a report on Monday, December 15th. Truist Financial lifted their price objective on IQVIA from $265.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Citigroup upped their target price on shares of IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research note on Wednesday, October 29th.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the sale, the insider owned 27,108 shares in the company, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

A number of institutional investors and hedge funds have recently modified their holdings of IQV. Physician Wealth Advisors Inc. increased its position in IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares during the last quarter. Westside Investment Management Inc. grew its stake in shares of IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 101 shares during the period. Measured Wealth Private Client Group LLC purchased a new stake in shares of IQVIA during the 3rd quarter valued at about $30,000. Atlantic Union Bankshares Corp bought a new position in shares of IQVIA in the 3rd quarter worth approximately $36,000. Finally, Root Financial Partners LLC purchased a new position in shares of IQVIA in the third quarter worth approximately $43,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Down 0.2%

IQV stock opened at $242.70 on Friday. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $247.05. The company has a market capitalization of $41.33 billion, a price-to-earnings ratio of 33.29, a price-to-earnings-growth ratio of 2.47 and a beta of 1.36. The business’s 50 day moving average price is $224.37 and its two-hundred day moving average price is $200.48. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm’s revenue was up 5.2% on a year-over-year basis. During the same period in the previous year, the company posted $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts forecast that IQVIA will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.